Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

US biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.

A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug ...

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...

Lenacapavir has shown high efficacy in managing multidrug-resistant cases offering hope to patients with limited alternatives A significant breakthrough in treating the Human Immunodeficiency Virus HI ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...